Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
Josh Makower, partner at venture capital investor New Enterprise Associates (NEA), has worked within life sciences for more than 20 years. He has learnt that “IP is a must” in the industry, due to the extensive time and costs involved in bringing a health product to market.
“If we did not believe the idea could be protected, there would be no interest in investing,” he explains.
Makower adds: “IP factors in very heavily when we’re looking at new companies, and the breadth and novelty of an invention as well as whether it can be practised without infringement is a fundamental screen before we’ll get involved.”
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
LSIPR 50 2018, Josh Makower, New Enterprise Associates, investment, medical technology, start-ups, novelty, IP infringement, patient care, medical devices